Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are established as part of the standard of care management for subsets of patients diagnosed with epithelial ovarian cancer, specifically in the maintenance setting following initial platinum-based chemotherapy.1 Beyond ovarian cancer, they have been investigated in a number of different tumor types including breast,2 pancreatic,3 and prostate4 cancers. This evidence concerns the gene PARP1 and neoplasm.